Table 1: Utilization of the facility (provide the total number of users that have utilized the facility by institution)

|  |  |
| --- | --- |
| **Institution** | **# Of Users** |
| University of Texas at Dallas | 4 |
| University of Texas Southwestern | 5 |

Table 2: Additional/Follow-On Funding (provide information in Table 2 about the funding source, type of funder, grant ID, title of grant, total amount received (direct plus indirect costs over the entire performance period), total project period of investment/award, a description of the subject of the funding, PI of the grant, and PI’s organization.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Funding Source** | **Type of Funder** | **Award ID** | **Title of Grant** | **Total Amount Received**  **(Direct and Indirect Costs for All Years)** | **Total Project Period of Investment/Award** | **Investment/Award Description** | **PI** | **PI Organization** |
| NIH | Federal Government | R01 CA12345 | Molecular Epidemiology of Cancer Cells | $1,000,000 | 09 Jun 2021- 08 Jun 2023 | This project aims to characterize the molecular epidemiology of cancer cells. | John Doe | University of Texas |

**Table 3: Publications citing the facility** Enter information about each publication in the table. Information includes PubMed ID, author, title, journal, and publication date.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PubMed ID** | **Authors** | **Title** | **Journal** | **Publication Date** |
| 12345 | Doe, JD, Doe, JN, Smith, DM, Smith, T | Identification of p53 as a cancer driver | Cancer Cell | 2021 Jun 15 |
|  |  |  |  |  |

**Table 4: Clinical trials supported by the facility** Enter trial name, clinicaltrials.gov identifier, clinical research categories (interventional and observational), primary purpose, primary anatomic cancer site, phase, clinical trial focus, clinical trial site, and patients enrolled.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Trial Name** | **Clinicaltrials.gov ID** | **Clinical Research Category** | **Primary Purpose\*** | **Primary Anatomic Cancer Site** | **Phase** | **Trial Focus\*\*** | **Trial Site** | **Total Number of Patients Accrued to Date** |
| TCC: Targeting Cancer Cells Study | NCT01234 | Interventional | Treatment | Leukemias | Phase II | Drug- Biologic | University of Texas | 100 |

**\*Primary Purpose categories:** Basic Science, Diagnostic, Health Services Research, Prevention, Screening, Supportive Care, Treatment.

**\*\* Trial Focus categories:** Bank Study, Biological-Other, Cell Therapy, Devices, Diagnostics, Drug-Biologic, Drug-Small Molecule, Immunotherapy, Procedures, Vaccine, Other.

**Table 5: Filed/granted patents resulting from research supported by the facility** Enter patent number, inventors, patent title, description, date of publication or issue, and date the patent application was filed and/or granted.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Patent Number** | **Inventors** | **Patent Title** | **Description** | **Date of Publication or Issue** | **Date of Patent Filed and/or granted** |
| 12/345, 678 | Doe, John; Doe, Jane, Smith, David | Receptor Inhibitors and Methods of Use Therof | Potent receptor inhibitors that reduce tumor size | 17 Dec 2020 | 17 Dec 2019 |